The distribution of pretreatment tumor characteristics, according to pCR or non-pCR, as presented in Table 4, indicates that patients with smaller tumors, a positive lymph node prior to treatment initiation, high proliferation, negative ER and/or PR status, and/or positive HER2 status were more likely to obtain pCR. This evidence concerns the gene PGR and neoplasm.